# The PTSD-Bone Axis: Evidence, Mechanisms, and Management

**Authors:** Olivia X. Jones, Kirsten D. Kelly, Stephanie K. Khoo, Ryan R. Kelly, Sara J. Sidles, Amanda C. LaRue

PMC · DOI: 10.1007/s11914-026-00957-2 · Current Osteoporosis Reports · 2026-03-16

## TL;DR

This paper reviews how PTSD affects bone health through stress-related biological pathways and suggests ways to manage the resulting skeletal issues.

## Contribution

The paper provides a comprehensive review of the PTSD-bone connection, highlighting novel therapeutic approaches like exosomal profiling and microbiome modulation.

## Key findings

- PTSD is linked to reduced bone mineral density and increased fracture risk.
- Stress disrupts bone remodeling via HPA axis, SNS activation, and inflammation.
- Personalized interventions and trauma-informed care may improve both mental and bone health.

## Abstract

This review explores the relationship between post-traumatic stress disorder (PTSD) and bone health, focusing on how chronic psychological stress influences skeletal integrity through neuroendocrine, immune, and behavioral pathways.

Clinical and preclinical studies demonstrate PTSD is associated with reduced bone mineral density, impaired healing, and fracture risk. Mechanistic insights implicate hypothalamic-pituitary-adrenal (HPA) axis dysregulation, sympathetic nervous system (SNS) overactivation, and chronic inflammation in disrupting bone remodeling. Additional risk modifiers include sex-specific biology, early-life adversity, and glucocorticoid sensitivity. However, selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), anti-inflammatory agents, and emerging tools like exosomal profiling and microbiome modulation show promise in mitigating stress-related bone loss.

PTSD contributes to skeletal fragility through complex, multisystem mechanisms. Trauma-informed care integrating bone health screening and personalized interventions may improve psychological and musculoskeletal outcomes. Future research should prioritize longitudinal, mechanistic studies to guide holistic management of trauma-related disease.

## Linked entities

- **Diseases:** post-traumatic stress disorder (MONDO:0005146)

## Full-text entities

- **Genes:** CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, POGZ (pogo transposable element derived with ZNF domain) [NCBI Gene 23126] {aka MRD37, WHSUS, ZNF280E, ZNF635, ZNF635m}, PRL (prolactin) [NCBI Gene 5617] {aka GHA1, pPRL}, BMP1 (bone morphogenetic protein 1) [NCBI Gene 649] {aka OI13, PCOLC, PCP, TLD}, TNFRSF11B (TNF receptor superfamily member 11b) [NCBI Gene 4982] {aka OCIF, OPG, PDB5, TR1}, Runx2 (runt related transcription factor 2) [NCBI Gene 12393] {aka AML3, CBF-alpha-1, Cbf, Cbfa-1, Cbfa1, LS3}, DKK1 (dickkopf Wnt signaling pathway inhibitor 1) [NCBI Gene 22943] {aka DKK-1, SK}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, Bglap2 (bone gamma-carboxyglutamate protein 2) [NCBI Gene 12097] {aka BGP2, Bglap1, Bgp, Og2, mOC-B}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, TNFSF11 (TNF superfamily member 11) [NCBI Gene 8600] {aka CD254, ODF, OPGL, OPTB2, RANKL, TNLG6B}, LRIG2 (leucine rich repeats and immunoglobulin like domains 2) [NCBI Gene 9860] {aka LIG-2, LIG2, UFS2}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, BAK1 (BCL2 antagonist/killer 1) [NCBI Gene 578] {aka BAK, BAK-LIKE, BCL2L7, CDN1}, CSF2 (colony stimulating factor 2) [NCBI Gene 1437] {aka CSF, GMCSF}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, Bmp2 (bone morphogenetic protein 2) [NCBI Gene 12156] {aka Bmp2a}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, Epo (erythropoietin) [NCBI Gene 24335], BCL2L11 (BCL2 like 11) [NCBI Gene 10018] {aka BAM, BIM, BOD}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, PTK2B (protein tyrosine kinase 2 beta) [NCBI Gene 2185] {aka CADTK, CAKB, FADK2, FAK2, PKB, PTK}, BCL2L1 (BCL2 like 1) [NCBI Gene 598] {aka BCL-XL/S, BCL2L, BCLX, Bcl-X, PPP1R52}, Nr3c1 (nuclear receptor subfamily 3, group C, member 1) [NCBI Gene 14815] {aka GR, Grl-1, Grl1}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, KITLG (KIT ligand) [NCBI Gene 4254] {aka DCUA, DFNA69, FPH2, FPHH, KL-1, Kitl}, SOST (sclerostin) [NCBI Gene 50964] {aka CDD, DAND6, SOST1, VBCH}, Epor (erythropoietin receptor) [NCBI Gene 24336]
- **Diseases:** Trauma (MESH:D014947), estrogen deficiency (MESH:D056828), health (OMIM:603663), mTBI (MESH:D001924), polytrauma (MESH:D009104), Sleep deprivation (MESH:D012892), Musculoskeletal Trauma (MESH:D009140), Disrupted sleep and circadian rhythm disturbances (MESH:D020178), bone deterioration (MESH:D001847), bone decay (MESH:D003731), glucocorticoid resistance (MESH:C564221), neuropsychiatric medications (MESH:D000069279), depression (MESH:D003866), hand and forearm injuries (MESH:D005543), disease (MESH:D004194), PTSD (MESH:D013313), Insomnia (MESH:D007319), mood dysregulation (MESH:D019964), Sleep loss (MESH:D012893), BMD (MESH:D001851), mental disorders (MESH:D001523), Chronic pain (MESH:D059350), neuroinflammation (MESH:D000090862), substance use disorders (MESH:D019966), pain (MESH:D010146), Osteoporosis (MESH:D010024), bone fragility (MESH:C536063), cardiovascular conditions (MESH:D002318), immune dysfunction (MESH:D007154), Dysbiosis (MESH:D064806), hypertension (MESH:D006973), hyperprolactinemia (MESH:D006966), systemic (MESH:D015619), HPA (MESH:D007029), adiposity (MESH:D018205), skeletal fragility (MESH:D005600), fracture (MESH:D050723), Inflammatory (MESH:D007249), neurodegeneration (MESH:D019636), testosterone deficiency (MESH:D007153), skeletal degeneration (MESH:D009410), traumatic brain injury (MESH:D000070642), anxiety (MESH:D001007), Diabetes (MESH:D003920), hypogonadism (MESH:D007006), intrusion (MESH:C537310), psychiatric distress (MESH:D012128)
- **Chemicals:** ROS (MESH:D017382), Phyllanthin (MESH:C517985), Ciurea (-), calcium (MESH:D002118), cortisol (MESH:D006854), catecholamines (MESH:D002395), aspirin (MESH:D001241), CE-123 (MESH:C000628267), steroid (MESH:D013256), ARA290 (MESH:C576178), vitamin D (MESH:D014807), Testosterone (MESH:D013739), alcohol (MESH:D000438), propranolol (MESH:D011433), glucose (MESH:D005947), norepinephrine (MESH:D009638), lipids (MESH:D008055), epinephrine (MESH:D004837), Duloxetine hydrochloride (MESH:D000068736), fluoxetine (MESH:D005473), dopamine (MESH:D004298), short-chain fatty acids (MESH:D005232)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Mycolicibacterium vaccae (species) [taxon 1810], Rattus norvegicus (brown rat, species) [taxon 10116], gut metagenome (species) [taxon 749906], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12992440/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12992440/full.md

## References

2 references — full list in the complete paper: https://tomesphere.com/paper/PMC12992440/full.md

---
Source: https://tomesphere.com/paper/PMC12992440